Sort   by:  
 Page size 
UnknownMicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.
Not available
S-EPMC5721230 | biostudies-literature
UnknownA review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.
Not available
S-EPMC3668267 | biostudies-literature
ProteomicsMEIS homeodomain proteins facilitate PARP1/ARTD1-mediated eviction of histone H1
Pre–B-cell leukemia homeobox (PBX) and myeloid ecotropic viral integration site (MEIS) proteins control cell fate decisions in many physiological and pathophysiological contexts, but how these proteins function mechanistically remains poorly defined. Focusing on the first hours of neuronal different...
ORGANISM(S): Mus musculus (Mouse) Homo sapiens (Human) 
2017-07-21 | PXD007078 | Pride
Parp1 Meis Histone h1 
UnknownMEIS homeodomain proteins facilitate PARP1/ARTD1-mediated eviction of histone H1.
Not available
S-EPMC5584172 | biostudies-literature
UnknownArginine Methylation Regulates MEIS2 Nuclear Localization to Promote Neuronal Differentiation of Adult SVZ Progenitors.
Not available
S-EPMC5998649 | biostudies-literature
UnknownTesting of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.
Not available
S-EPMC3154998 | biostudies-literature
UnknownTargeting epigenetic features in clear cell sarcomas based on patient-derived cell lines.
Not available
S-EPMC9884415 | biostudies-literature
ProteomicsProteogenomic subtyping of chronic lymphocytic leukemia identifies subgroups with contrasting clinical outcome and distinct ex-vivo drug response profile
We have performed a comprehensive proteomic analysis of clinical patient samples of chronic lymphocytic leukemia (CLL) alongside genome-, transcriptome- and ex-vivo drug response profiling. Trisomy 12 and IGHV mutation status had the strongest impact on the proteome and transcriptome; and SF3B1 muta...
ORGANISM(S): Homo sapiens (Human) 
2024-06-21 | PXD017453 | Pride
Lymphoblast B-cell Chronic lymphoblastic leukemia Proteogenomics Human Lc-ms Leukemia Cancer Clinical samples. Hirief Proteomics 
ProteomicsProteogenomic subtyping of chronic lymphocytic leukemia identifies subgroups with contrasting clinical outcome and distinct ex-vivo drug response profile
We have performed a comprehensive proteomic analysis of clinical patient samples of chronic lymphocytic leukemia (CLL) alongside genome-, transcriptome- and ex-vivo drug response profiling. Trisomy 12 and IGHV mutation status had the strongest impact on the proteome and transcriptome; and SF3B1 muta...
ORGANISM(S): Homo sapiens (Human) 
2022-10-17 | PXD028936 | Pride
Lymphoblast B-cell Chronic lymphoblastic leukemia Proteogenomics Human Lc-ms Leukemia Cancer Clinical samples. Hirief Proteomics 
ProteomicsProteogenomic subtyping of chronic lymphocytic leukemia identifies subgroups with contrasting clinical outcome and distinct ex-vivo drug response profile – DIA Validation
We have performed a comprehensive proteomic analysis of clinical patient samples of chronic lymphocytic leukemia (CLL) alongside genome-, transcriptome- and ex-vivo drug response profiling. Trisomy 12 and IGHV mutation status had the strongest impact on the proteome and transcriptome; and SF3B1 muta...
ORGANISM(S): Homo sapiens (Human) 
2022-10-19 | PXD024544 | Pride
Lymphoblast B-cell Chronic lymphoblastic leukemia Human Leukemia Cancer Proteogenomics Hirief Dia Lc-ms Clinical samples Data independent acquisition Proteomics 
Sort   by:  
 Page size